Overview

* Intuitive Surgical ( ISRG ) Q3 revenue grows 23% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting operational efficiency

* Company repurchased 4 mln shares for $1.92 bln in Q3

Outlook

* Company expects 2025 da Vinci procedure growth of 17% to 17.5%

* Non-GAAP gross profit margin expected at 67% to 67.5% in 2025

* Non-GAAP operating expenses to grow 11% to 13% in 2025

Result Drivers

* PROCEDURE GROWTH - Worldwide procedures increased 20%, with da Vinci up 19% and Ion up 52%

* SYSTEM PLACEMENTS - 427 da Vinci systems placed, including 240 da Vinci 5 systems

* INSTALLED BASE EXPANSION - Installed base of da Vinci systems grew 13%, Ion systems 30%

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $2.50 $2.40

Revenue bln bln (24

Analysts

)

Q3 Beat $2.40 $1.98

Adjusted (22

EPS Analysts

)

Q3 EPS $1.95

Q3 Beat $867 mln $718.60

Adjusted mln (19

Net Analysts

Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Intuitive Surgical Inc ( ISRG ) is $591.00, about 22.4% above its October 20 closing price of $458.47

* The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 64 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)